These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 1919529)

  • 1. Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of human immunodeficiency virus type 1.
    Langedijk JP; Back NK; Durda PJ; Goudsmit J; Meloen RH
    J Gen Virol; 1991 Oct; 72 ( Pt 10)():2519-26. PubMed ID: 1919529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformation of the principal neutralizing determinant of human immunodeficiency virus type 1 in complex with an anti-gp120 virus neutralizing antibody studied by two-dimensional nuclear magnetic resonance difference spectroscopy.
    Zvi A; Feigelson DJ; Hayek Y; Anglister J
    Biochemistry; 1997 Jul; 36(28):8619-27. PubMed ID: 9214308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
    Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
    Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
    Davis D; Stephens DM; Carne CA; Lachmann PJ
    J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of viral replication by monoclonal antibodies directed against human immunodeficiency virus gp120.
    Niedrig M; Harthus HP; Hinkula J; Bröker M; Bickhard H; Pauli G; Gelderblom HR; Wahren B
    J Gen Virol; 1992 Sep; 73 ( Pt 9)():2451-5. PubMed ID: 1383412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
    Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
    J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1.
    Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S
    J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
    D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
    AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An immunodominant epitope in a functional domain near the N-terminus of human granulocyte-macrophage colony-stimulating factor identified by cross-reaction of synthetic peptides with neutralizing anti-protein and anti-peptide antibodies.
    Beffy P; Rovero P; Di Bartolo V; Laricchia Robbio L; Dané A; Pegoraro S; Bertolero F; Revoltella RP
    Hybridoma; 1994 Dec; 13(6):457-68. PubMed ID: 7737670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization.
    Broliden PA; Ljunggren K; Hinkula J; Norrby E; Akerblom L; Wahren B
    J Virol; 1990 Feb; 64(2):936-40. PubMed ID: 2296090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Permissive residues within the minimal epitopes of neutralizing monoclonal antibodies to the V3 loop of HIV-1.
    Laisney IL; Benjamin H; Gefter M; Strosberg AD
    Eur J Immunol; 1996 Jul; 26(7):1634-40. PubMed ID: 8766572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1.
    Langedijk JP; Back NK; Kinney-Thomas E; Bruck C; Francotte M; Goudsmit J; Meloen RH
    Arch Virol; 1992; 126(1-4):129-46. PubMed ID: 1381908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
    Neurath AR; Strick N; Lee ES
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 peptide vaccine candidates: selecting constrained V3 peptides with highest affinity to antibody 447-52D.
    Mester B; Manor R; Mor A; Arshava B; Rosen O; Ding FX; Naider F; Anglister J
    Biochemistry; 2009 Aug; 48(33):7867-77. PubMed ID: 19552398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
    Gorny MK; Xu JY; Karwowska S; Buchbinder A; Zolla-Pazner S
    J Immunol; 1993 Jan; 150(2):635-43. PubMed ID: 7678279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.